Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. - Wikidata - wikimedia - TriplyDB

Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease.

Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease.

http://www.wikidata.org/entity/Q35287117

about

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease Novel subcellular localization for α-synuclein: possible functional consequences Membrane omega-3 fatty acids modulate the oligomerisation kinetics of adenosine A2A and dopamine D2 receptors.Role of sulfatide in normal and pathological cells and tissues Lipid-binding properties of human ApoD and Lazarillo-related lipocalins: functional implications for cell differentiation.Homeostasis of phospholipids - The level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens.Cholesterol-mediated activation of acid sphingomyelinase disrupts autophagy in the retinal pigment epithelium Membrane cholesterol access into a G-protein-coupled receptor.Cholesterol in the Pathogenesis of Alzheimer's, Parkinson's Diseases and Autism: Link to Synaptic Dysfunction Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms Choline-containing phospholipids in microdissected human Alzheimer's disease brain senile plaque versus neuropil.RaftProt: mammalian lipid raft proteome database.Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA.Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice Major Alterations of Phosphatidylcholine and Lysophosphotidylcholine Lipids in the Substantia Nigra Using an Early Stage Model of Parkinson's Disease.Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.Loss of parkin promotes lipid rafts-dependent endocytosis through accumulating caveolin-1: implications for Parkinson's disease Selective effect of cell membrane on synaptic neurotransmission.Biophysical characterization of membrane proteins in nanodiscs.First experimental evidence of dopamine interactions with negatively charged model biomembranes DJ-1 deficiency impairs glutamate uptake into astrocytes via the regulation of flotillin-1 and caveolin-1 expression.Fatting the brain: a brief of recent research A biological perspective of CSF lipids as surrogate markers for cognitive status in HIV Dietary fat intake, pesticide use, and Parkinson's disease.Brain banks as key part of biochemical and molecular studies on cerebral cortex involvement in Parkinson's disease.Ceramide function in the brain: when a slight tilt is enough.Oestrogens as modulators of neuronal signalosomes and brain lipid homeostasis related to protection against neurodegeneration.Lipid rafts in neurodegeneration and neuroprotection.Pathogenic role of ganglioside metabolism in neurodegenerative diseases.Transcriptional network analysis in frontal cortex in Lewy body diseases with focus on dementia with Lewy bodies.Membrane lipids as therapeutic targets for Parkinson's disease: a possible link between Lewy pathology and membrane lipids.Addition of docosahexaenoic acid, but not arachidonic acid, activates glutathione and thioredoxin antioxidant systems in murine hippocampal HT22 cells: potential implications in neuroprotection.Peroxisomal Dysfunction in Age-Related Diseases.Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson’s disease.Structural and functional roles of ether lipids.Sphingolipids: membrane microdomains in brain development, function and neurological diseases.A high fat diet containing saturated but not unsaturated fatty acids enhances T cell receptor clustering on the nanoscale.Characterization of lipid rafts in human platelets using nuclear magnetic resonance: A pilot study Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease.Genotype-induced changes in biophysical properties of frontal cortex lipid raft from APP/PS1 transgenic mice.

P2860

Q24324577-F2B2C496-BEAD-4742-AEF7-A2E7DE2D4D9D Q26827605-A3A188FF-E225-495C-945C-AB04670EC54D Q27300848-684FB355-D57D-403D-A621-3B5B157EF186 Q28267288-4239CA69-43F1-4BC5-BE49-D76A7E2684A6 Q30155078-09834B94-5194-4F59-B6FE-55A5B59475B6 Q30417407-9D49F2FA-7AC5-4674-BE2D-459DC81C53B3 Q30612009-094EDFFB-7005-42D3-AD0B-BAD57B357763 Q30839707-14CA80CB-6BB1-4F9D-BD5D-7B655C934C40 Q33607803-6D7BBB7B-CC8A-40C3-B51E-28E38EB999A6 Q34109658-DA539E62-1ECD-429F-8705-635B205A3069 Q34421898-B5DCFB8D-351D-465B-904A-8ABDC93BBFC6 Q35253880-B9A0214A-E23B-43BD-97D0-1D3577505DA1 Q35507433-AFA06271-80FB-4F05-8E37-C630947D3EAC Q35951218-1B01D38C-2132-4E07-8B96-A8E0BF612CA5 Q36088639-3C81D42C-453F-49A9-94B3-B337B1192758 Q36175217-324C3336-8295-478A-A61A-1ECA74D162A3 Q36336839-D829077E-A550-404E-9A0E-AD3036E4287D Q36499795-74862EBE-A884-451A-ADA0-E8C15A2B90D0 Q36718332-2B08658E-5DA8-4868-8E22-F68AA1DE3BC5 Q37025882-66B40834-EB2D-4BD1-AFA3-45B54A809466 Q37040352-EB4B4109-7F2B-4D7E-87E3-C2DCEEF706E7 Q37155461-3B1E8170-C2AB-4755-88D3-6EC7665D522B Q37541514-9B5682D0-9B65-477A-8C6D-E820A454D701 Q37606627-757CC40E-9DA4-44CD-849D-28FD50AA3FD7 Q37982151-C31E5F20-13AA-4E31-9224-C1F8B17550BA Q38021345-33BB6F10-6D7E-4E7E-BB2B-1D6388010BB2 Q38116551-FA4495C4-2A92-485D-8DD8-11B4D22BC207 Q38173298-136D9AB9-1394-44CE-B7A0-903E8233BEEA Q38218040-29931A65-5CDE-4129-BF4E-D2E8FEC1AE4C Q38435692-F5067092-2A2C-401A-A783-46570BEE7044 Q38648684-0C1C9295-2899-4443-BC02-967842B0C3DC Q38933785-8C1D6FB8-70E8-4EA4-B055-9945D920D07C Q39073343-3F4BC362-7631-4D2E-AE3D-3D9288493686 Q39193441-1B93B8C2-F8AD-4575-BFDA-2F2328734C35 Q39317295-18789FAE-D34E-4E84-9018-E27053BD5489 Q39342245-603BA540-1EE3-4E6C-8E5E-5370079AD311 Q40768511-8008C0E3-ADEC-45A4-B869-0E9DBF3C1D3A Q41682257-DF8DE8B3-BA6A-4FCF-989C-06C2F9250911 Q42108095-2ABE7C28-21F6-4D13-AF5E-4F46DDC595B7 Q42355559-D7E42C09-5A50-4474-8E24-270A7E23AA30

P2860

Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease.

http://www.wikidata.org/entity/Q35287117

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Severe alterations in lipid co ...... ncidental Parkinson's disease.

@ast

Severe alterations in lipid co ...... ncidental Parkinson's disease.

@en

type

label

Severe alterations in lipid co ...... ncidental Parkinson's disease.

@ast

Severe alterations in lipid co ...... ncidental Parkinson's disease.

@en

prefLabel

Severe alterations in lipid co ...... ncidental Parkinson's disease.

@ast

Severe alterations in lipid co ...... ncidental Parkinson's disease.

@en

P1433

Q35287117-12670736-7A44-47C0-9130-99827AAD5FD3

P1476

Q35287117-3988DA3E-3D77-4CA4-87E4-69609D6FCFD1

P2093

Q35287117-03D829ED-5A60-4942-987C-F278C5FD2834

Q35287117-0917E147-9A4B-48EB-800B-8D1BF2A616EC

Q35287117-34E970B0-415F-4141-BA1E-55F5C6D17FE9

Q35287117-3FD7D5CE-A7F3-4D21-B9E8-AADEBB9ACD23

Q35287117-5983A869-A542-40D9-9ADF-5F1DFDFD3DBC

Q35287117-B86C2943-DE95-4ABA-BA27-D27A49AE7998

Q35287117-F5A5C45B-A9F8-455E-9917-8DD5E535A492

P2860

Q35287117-00C531B1-9D29-4379-B91F-9C4997AC6223

Q35287117-0281F113-2F69-4F36-AE63-546A52F5DE70

Q35287117-066626DE-B9A8-4E9A-B2C4-9CF85FDDFD6B

Q35287117-09076CD8-73B0-4F15-B254-93A810B7CEBF

Q35287117-0B152C8A-28AD-4DEA-9736-9AB1F9299DF7

Q35287117-108C15A1-C7B5-4517-99CF-21A0F6FAC5F4

Q35287117-1261BBAE-9C9E-4FEC-846E-253084AC1DC6

Q35287117-19FC6679-FDBE-4744-878C-606730FAF7FD

Q35287117-1A9B26C5-CA06-4004-BED4-5A92BC1BCFDC

Q35287117-1CD2E25B-E312-4D22-A75C-09DF2C70F3EB

P2888

Q35287117-741F85C5-DABE-4C73-9E37-A2A00CDDC596

P304

Q35287117-7658B84E-07A5-40BA-BB06-345CBFC97EE9

P31

Q35287117-1F311A94-E546-479C-B333-B87799373B3B

P356

Q35287117-0656BC69-ACF5-4200-B328-5CC3CA9D142D

P407

Q35287117-4E9496ED-DCF6-4C72-99F3-C2F972BE8757

P433

Q35287117-3EDC1331-24FD-4B14-9109-285169E2A255

P478

Q35287117-33E0B396-CEBD-45D5-89D4-67057E16A452

P577

Q35287117-5E4F38E9-956B-4901-96C8-125D8D86D4EA

P5875

Q35287117-6F3F8F3D-CDF5-4161-ADC3-97BBF19A242B

P6179

Q35287117-BB869112-F180-444C-AE37-EAA5886A32DB

P698

Q35287117-9695875B-E4EC-4B72-A1A1-27078D984F4D

P921

Q35287117-8A639863-1C69-4F9E-B711-6D79F66A5FC2

P932

Q35287117-A52720E4-946D-4183-8692-D12E65AE4B87

P356

MOLMED.2011.00119

P1433

Molecular Medicine

P1476

Severe alterations in lipid co ...... ncidental Parkinson's disease.

@en

P2093

Gabriel Santpere

http://www.w3.org/2001/XMLSchema#string

Isidre Ferrer

http://www.w3.org/2001/XMLSchema#string

Laia Torrent

http://www.w3.org/2001/XMLSchema#string

Mario Díaz

http://www.w3.org/2001/XMLSchema#string

Noemí Fabelo

http://www.w3.org/2001/XMLSchema#string

Raquel Marín

http://www.w3.org/2001/XMLSchema#string

Virginia Martín

http://www.w3.org/2001/XMLSchema#string

P2860

The challenge of lipid rafts

Staging of brain pathology related to sporadic Parkinson's disease

Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases

Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies

Plasmenylethanolamine is the major storage depot for arachidonic acid in rabbit vascular smooth muscle and is rapidly hydrolyzed after angiotensin II stimulation

Stages in the development of Parkinson's disease-related pathology

Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes

Oxidative stress in Parkinson's disease

Structure and function of sphingolipid- and cholesterol-rich membrane rafts

Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease.

P2888

molmed.2011.00119

P304

1107-1118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2119/MOLMED.2011.00119

http://www.w3.org/2001/XMLSchema#string

P407

P433

9-10

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51455595

http://www.w3.org/2001/XMLSchema#string

P6179

1068965401

http://www.w3.org/2001/XMLSchema#string

P698

21717034

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3188884

http://www.w3.org/2001/XMLSchema#string